PARP inhibitor (olaparib, niraparib, or rucaparib) maintenance treatment is a standard treatment option in patients with high-grade serous tubo-ovarian and peritoneal cancers following surgery and chemotherapy. The gene discussed is PARP1; the disease is peritoneum cancer.